Meropenem-Vaborbactam Combination for Resistant Gram-Negative Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gram-negative bacteria, particularly carbapenem-resistant Enterobacteriaceae (CRE), are resistant to current antibiotics, posing a significant threat to immunocompromised patients with high mortality rates due to infections such as pneumonia and bloodstream infections.
Innovation Solution
Administer a combination of vaborbactam and meropenem to subjects, including immunocompromised individuals with underlying malignancies or immune compromise, to treat bacterial infections effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibiotics are used to treat gram-negative bacterial infections, then treatment is provided, but the bacteria become resistant and mortality rates increase
Solution Approach 1:
The patent combines vaborbactam (a beta-lactamase inhibitor) with meropenem (a carbapenem antibiotic) to create a synergistic treatment regimen. This combination addresses bacterial resistance by using the inhibitor to prevent enzyme-mediated drug degradation while the antibiotic provides direct bacterial cell wall synthesis inhibition, thereby maintaining efficacy against resistant strains.
Solution Approach 2:
The patent modifies the pharmacological parameters of the treatment by using a novel beta-lactamase inhibitor mechanism (vaborbactam) in combination with traditional carbapenems. This parameter change in the molecular mechanism allows the treatment to overcome resistance pathways that render conventional single-agent carbapenem therapy ineffective.
2Productivity
If broad-spectrum antimicrobials are used frequently, then bacterial infections are treated, but antibiotic resistance develops and patient outcomes worsen
Solution Approach 1:
The patent extracts the beta-lactamase inhibition function from general antibiotic therapy and integrates it specifically with carbapenem class antibiotics. This targeted extraction allows the treatment to address resistance mechanisms specific to gram-negative bacteria without requiring broad-spectrum coverage, thereby maintaining patient outcomes while reducing selective pressure for resistance.
3Ease of operation
If immunocompromised patients receive standard antibiotic treatment, then infection is addressed, but mortality rates remain high due to underlying immune compromise
Solution Approach 1:
The patent implements preliminary action by using vaborbactam to preemptively inhibit beta-lactamase enzymes before the meropenem can be degraded. This preliminary inhibition ensures that the antibiotic remains active throughout the infection treatment period, providing more reliable bacterial killing in immunocompromised patients who require sustained effective concentrations.
Data Source
AI summary
Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.